Logo image of CRDL

CARDIOL THERAPEUTICS INC-A (CRDL) Stock Fundamental Analysis

NASDAQ:CRDL - Nasdaq - CA14161Y2006 - Common Stock - Currency: USD

1.2  -0.1 (-7.69%)

After market: 1.26 +0.06 (+5%)

Fundamental Rating

1

CRDL gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. CRDL may be in some trouble as it scores bad on both profitability and health. CRDL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRDL has reported negative net income.
CRDL had a negative operating cash flow in the past year.
CRDL had negative earnings in each of the past 5 years.
In the past 5 years CRDL always reported negative operating cash flow.
CRDL Yearly Net Income VS EBIT VS OCF VS FCFCRDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

CRDL's Return On Assets of -206.26% is on the low side compared to the rest of the industry. CRDL is outperformed by 90.27% of its industry peers.
With a Return On Equity value of -346.42%, CRDL is not doing good in the industry: 77.84% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -206.26%
ROE -346.42%
ROIC N/A
ROA(3y)-54.17%
ROA(5y)-76.13%
ROE(3y)-66.78%
ROE(5y)-89.82%
ROIC(3y)N/A
ROIC(5y)N/A
CRDL Yearly ROA, ROE, ROICCRDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

CRDL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDL Yearly Profit, Operating, Gross MarginsCRDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for CRDL has been increased compared to 1 year ago.
Compared to 5 years ago, CRDL has more shares outstanding
CRDL has a worse debt/assets ratio than last year.
CRDL Yearly Shares OutstandingCRDL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
CRDL Yearly Total Debt VS Total AssetsCRDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

CRDL has an Altman-Z score of -8.32. This is a bad value and indicates that CRDL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.32, CRDL is doing worse than 71.35% of the companies in the same industry.
CRDL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
CRDL has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: CRDL outperforms 54.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -8.32
ROIC/WACCN/A
WACCN/A
CRDL Yearly LT Debt VS Equity VS FCFCRDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

CRDL has a Current Ratio of 2.49. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
CRDL has a Current ratio (2.49) which is in line with its industry peers.
CRDL has a Quick Ratio of 2.49. This indicates that CRDL is financially healthy and has no problem in meeting its short term obligations.
CRDL has a Quick ratio (2.49) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.49
Quick Ratio 2.49
CRDL Yearly Current Assets VS Current LiabilitesCRDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CRDL have decreased strongly by -22.73% in the last year.
EPS 1Y (TTM)-22.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 35.01% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.18%
EPS Next 2Y-8.09%
EPS Next 3Y-19.98%
EPS Next 5Y35.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRDL Yearly Revenue VS EstimatesCRDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
CRDL Yearly EPS VS EstimatesCRDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRDL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRDL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDL Price Earnings VS Forward Price EarningsCRDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDL Per share dataCRDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

CRDL's earnings are expected to decrease with -19.98% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.09%
EPS Next 3Y-19.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRDL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIOL THERAPEUTICS INC-A

NASDAQ:CRDL (2/21/2025, 8:10:51 PM)

After market: 1.26 +0.06 (+5%)

1.2

-0.1 (-7.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-31 2025-03-31/amc
Inst Owners9.66%
Inst Owner Change-94.25%
Ins Owners4.65%
Ins Owner ChangeN/A
Market Cap99.13M
Analysts82.5
Price Target6.91 (475.83%)
Short Float %1.82%
Short Ratio4.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.24%
Min EPS beat(2)-47.06%
Max EPS beat(2)24.59%
EPS beat(4)2
Avg EPS beat(4)-6.52%
Min EPS beat(4)-47.06%
Max EPS beat(4)24.59%
EPS beat(8)6
Avg EPS beat(8)7.31%
EPS beat(12)10
Avg EPS beat(12)12.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.48%
PT rev (3m)-3.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.09%
EPS NY rev (1m)-8%
EPS NY rev (3m)-20%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.49
P/tB 13.49
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -206.26%
ROE -346.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.17%
ROA(5y)-76.13%
ROE(3y)-66.78%
ROE(5y)-89.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.49%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.49
Quick Ratio 2.49
Altman-Z -8.32
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)20.75%
Cap/Depr(5y)71.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-25.18%
EPS Next 2Y-8.09%
EPS Next 3Y-19.98%
EPS Next 5Y35.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.74%
EBIT Next 3Y-0.33%
EBIT Next 5Y46.22%
FCF growth 1Y-16.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.22%
OCF growth 3YN/A
OCF growth 5YN/A